Drug · CHEMBL1069
Comparisons in its trials77
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
1 to 20 of 77
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| LCZ696 vs Enalapril: serious adverse events | 1,937 of 4,203 | 2,142 of 4,229 | 8,432 | NCT01035255 | Trial comparisons |
| LCZ696 vs Enalapril: Number of Patients With First Confirmed Renal Dysfunction | 94 of 4,187 | 108 of 4,212 | 8,399 | NCT01035255 | Trial comparisons |
| LCZ696 vs Enalapril: Number of Patients - All-cause Mortality | 711 of 4,187 | 835 of 4,212 | 8,399 | NCT01035255 | Trial comparisons |
| LCZ696 (Sacubitril/Valsartan) vs Ramipril: Number of Participants With a Confirmed Composite of HF Hospitalization or Outpatient HF | 201 of 2,830 | 237 of 2,831 | 5,661 | NCT02924727 | Trial comparisons |
| LCZ696 (Sacubitril/Valsartan) vs Ramipril: Number of Participants With a Confirmed Composite of CV Death or HF Hospitalization | 308 of 2,830 | 335 of 2,831 | 5,661 | NCT02924727 | Trial comparisons |
| LCZ696 (Sacubitril/Valsartan) vs Ramipril: All-cause Mortality for Full Analysis Set (FAS) | 213 of 2,830 | 242 of 2,831 | 5,661 | NCT02924727 | Trial comparisons |
| LCZ696 (Sacubitril/Valsartan) vs Ramipril: Number of Participants With a Confirmed Composite of CV Death, Non-fatal Spontaneous Myocardial Infarction or Non-fatal Stroke | 315 of 2,830 | 349 of 2,831 | 5,661 | NCT02924727 | Trial comparisons |
| LCZ696 vs Valsartan: All-cause Mortality | 342 of 2,407 | 349 of 2,389 | 4,796 | NCT01920711 | Trial comparisons |
| Valsartan vs Non-ARB: serious adverse events | 0 of 1,517 | 0 of 1,514 | 3,031 | NCT00149227 | Trial comparisons |
| Valsartan/Amlodipine 160/5 mg vs Amlodipine 10 mg: serious adverse events | 11 of 592 | 8 of 591 | 1,183 | NCT00437645 | Trial comparisons |
| Combination Therapy: Aliskiren + Valsartan vs Monotherapy: Valsartan: serious adverse events | 9 of 574 | 9 of 565 | 1,139 | NCT00927394 | Trial comparisons |
| LCZ696 Pre-discharge Treatment Initiation vs LCZ696 Post-discharge Treatment Initiation: Percentage of Patients Achieving and Maintaining Either LCZ696 100 mg and/or 200 mg Bid | 306 of 493 | 335 of 489 | 982 | NCT02661217 | Trial comparisons |
| LCZ696 Pre-discharge Treatment Initiation vs LCZ696 Post-discharge Treatment Initiation: Percentage of Patients Achieving the Target Dose of LCZ696 200 mg Bid at 10 Weeks Post Randomization | 224 of 493 | 248 of 489 | 982 | NCT02661217 | Trial comparisons |
| LCZ696 Pre-discharge Treatment Initiation vs LCZ696 Post-discharge Treatment Initiation: Percentage of Patients Achieving and Maintaining Any Dose of LCZ696 | 424 of 493 | 438 of 489 | 982 | NCT02661217 | Trial comparisons |
| Enalapril vs Sacubitril/Valsartan (LCZ696): Number of Patients With Incidences of Symptomatic Hypotension | 56 of 441 | 66 of 440 | 881 | NCT02554890 | Trial comparisons |
| Enalapril vs Sacubitril/Valsartan (LCZ696): Number of Patients With Incidences of Angioedema | 11 of 441 | 1 of 440 | 881 | NCT02554890 | Trial comparisons |
| Enalapril vs Sacubitril/Valsartan (LCZ696): Number of Patients With Incidences of Hyperkalemia | 41 of 441 | 51 of 440 | 881 | NCT02554890 | Trial comparisons |
| Aggressive Treatment Regimen (5/320 mg to 10/320 mg) vs Moderate Treatment Regimen (5/160 mg): serious adverse events | 4 of 369 | 10 of 359 | 728 | NCT00666536 | Trial comparisons |
| Maintenance Phase: SZC vs Maintenance Phase: Placebo: Incidence of RAASi Reduction | 55 of 359 | 128 of 354 | 713 | NCT05056727 | Trial comparisons |
| Maintenance Phase: SZC vs Maintenance Phase: Placebo: Incidence of the Composite of Kidney Failure Outcomes | 7 of 359 | 4 of 354 | 713 | NCT05056727 | Trial comparisons |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1069/comparisons